Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database.
Stephanie H ReadNadia QuignotRaissa Kapso-KapnangErin ComerfordYing ZhengCorona GainfordMedha SasaneAnne-Lise VataireLaure DelzongleFrancois-Clement BidardPublished in: Breast cancer research and treatment (2024)
This real-world analysis confirms the effectiveness of CDK4/6 inhibitor-based regimens in French patients and highlights the frequent use of chemotherapy as second line therapy.
Keyphrases
- metastatic breast cancer
- healthcare
- end stage renal disease
- cell cycle
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- systematic review
- peritoneal dialysis
- prognostic factors
- emergency department
- squamous cell carcinoma
- radiation therapy
- cell proliferation
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- bone marrow
- cell therapy
- rectal cancer
- health insurance